![]() |
|
|
Vol. 290, Issue 2, 594-602, August 1999
Department of Drug Metabolism and Pharmacokinetics,
Rhône-Poulenc Rorer, Collegeville, Pennsylvania (J.C.S., R.B.W.);
Department of Pharmacology and Toxicology, University of Texas Medical
Branch, Galveston, Texas (T.L.D., J.R.H.); Department of Structural
Analysis, Rhône-Poulenc Rorer, Collegeville, Pennsylvania (E.O.);
Selectide Corporation, Tucson, Arizona (G.R.H.)
RPR 106541 {20R-16
,17
-[butylidenebis(oxy)]-6
,9
-difluoro-11
-hydroxy-17
-(methylthio)androsta-4-en-3-one}
is an airway-selective steroid developed for the treatment of asthma.
Two metabolites produced by human liver microsomes were identified as
R- and S-sulfoxide diastereomers based on
liquid chromatography/mass spectrometry analysis, proton nuclear
magnetic resonance, and cochromatography with standards. Sulfoxide
formation was determined to be cytochrome P-450 (CYP)
3A4-dependent by correlation with CYP3A4-marker nifedipine oxidase
activity, inhibition by cyclosporin A and troleandomycin, and
inhibition of R- (70%) and S- (64%)
sulfoxide formation by anti-3A antibody. Expressed CYP2C forms
catalyzed RPR 106541 sulfoxidation; however, other phenotyping
approaches failed to confirm the involvement of CYP2C forms in these
reactions in human liver microsomes. Expressed CYP3A4 catalyzed the
formation of the sulfoxide diastereomers in a 1:1 ratio, whereas CYP3A5
displayed stereoselectivity for formation of the
S-diastereomer. The high rate of sulfoxidation by CYP3A4
and the blockage of oxidative metabolism at the electronically favored
6
-position provided advantages for RPR 106541 over other substrates
as an active site probe of CYP3A4. Therefore, oxidation of RPR 106541 by various CYP3A4 substrate recognition site (SRS) mutants was
assessed. In SRS-4, A305V and F304A showed dramatically reduced rates
of R-diastereomer formation (83 and 64% decreases, respectively), but S-diastereomer formation was affected
to a lesser extent. A370V (SRS-5) showed decreased formation of the R-sulfoxide (52%) but increased formation of the
S-diastereomer. In the SRS-2 region, the most dramatic
change in sulfoxide ratios was observed for L210A. In conclusion, the
structure of RPR 106541 imposes specific constraints on enzyme binding
and activity and thus represents an improved CYP3A4 probe substrate.
This article has been cited by other articles:
![]() |
P. A. Williams, J. Cosme, D. M. Vinkovic, A. Ward, H. C. Angove, P. J. Day, C. Vonrhein, I. J. Tickle, and H. Jhoti Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone Science, July 30, 2004; 305(5684): 683 - 686. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. Khan, Y. Q. He, T. L. Domanski, and J. R. Halpert Midazolam Oxidation by Cytochrome P450 3A4 and Active-Site Mutants: an Evaluation of Multiple Binding Sites and of the Metabolic Pathway That Leads to Enzyme Inactivation Mol. Pharmacol., March 1, 2002; 61(3): 495 - 506. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Domanski, Y.-A. He, G. R. Harlow, and J. R. Halpert Dual Role of Human Cytochrome P450 3A4 Residue Phe-304 in Substrate Specificity and Cooperativity J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 585 - 591. [Abstract] [Full Text] |
||||